BIOCORP Announces Partnership with AARDEX Group to Extend Smart Solutions for Precision Medication Adherence
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the design, development and manufacture of innovative medical devices, today announced an alliance with Belgium-based AARDEX Group, the world leader in medication adherence solutions.
This alliance is to combine BIOCORP’s connected add-on solutions for drug delivery devices with AARDEX’s proprietary Medication Event Monitoring System (MEMS®) and offer a comprehensive solution to patients and healthcare providers to effectively measure and manage medication adherence. The financial terms of the agreement have not been disclosed, however the first initiative will be to integrate BIOCORP’s Injay connected solution for Pre-filled syringes (PFS) to AARDEX’s MEMS Adherence Software (MEMS AS®), to target medicines delivered by PFS with potential applications in the field of Rheumatoid Arthritis, Multiple Sclerosis, Ophthalmology, Psoriasis or Cardiovascular diseases. The roadmap also includes integration with BIOCORP’s other connected devices, to cover further chronic conditions in the field of injectable, respiratory, and beyond.
David Dalla Vecchia, CEO and Financial Lead of AARDEX Group, said: "We are delighted to announce our partnership with BIOCORP. Our vision is to continuously innovate in data-driven medication adherence solutions to enhance digital therapeutics and patient empowerment. Partnering with BIOCORP - a true pioneer in connected devices - will significantly contribute to that objective and bring together a wealth of knowledge and experience to help meet the needs of today’s clinical trials, patients and healthcare providers.”
Éric Dessertenne, CEO of BIOCORP, concluded: “This collaboration with AARDEX Group brings a strong added value to our products and to our targeted users. Thanks to the integration with MEMS AS, a unique solution that analyzes deeply patient patterns and behaviors, we will go beyond just monitoring treatment adherence, by providing comprehensive and tailored solutions to boost patient’s engagement and effectively manage this issue. AARDEX specific expertise in clinical trials is also a strong asset and will enable us to create relationships with pharma companies right from the development stage of a drug”.
Medication adherence issues are well known by all healthcare stakeholders and its clinical and commercial impact have been quantified and heavily documented for many years now. The World Health Organization has stated that, in developed countries, adherence to long-term therapies in the general population is only around 50%. But this issue is not limited to commercialized drugs and real-life conditions, it also massively affects clinical trials, which impacts assessment of drug efficacy.
ABOUT AARDEX GROUP
AARDEX Group is the world leader in digital solutions to measure and manage medication adherence. Located in Belgium, in Switzerland and in the U.S., AARDEX develops and markets digital solutions for adherence-enhancing strategies in clinical trials, research settings, and professional healthcare systems. AARDEX is the central actor of a complete ecosystem that combines its MEMS® Adherence Software with a wide range of smart packages and devices that measure patient adherence across all routes of drug administration. Our vision is to continuously innovate in data-driven medication adherence solutions to enhance digital therapeutics and patient empowerment.
For more information, visit www.aardexgroup.com
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This intelligent sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of diabetics. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 54 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200930005883/en/
Contact information
FOR MEDIA ENQUIRIES - ON BEHALF OF AARDEX GROUP
Sophie Beattie
sophie@discovery-pr.com
Mobile: + 44 (0) 7494 129 339
BIOCORP CONTACTS
Jacques Gardette
Chairman of the Board
investisseurs@biocorp.fr
Éric Dessertenne
Chief Executive Officer
Sylvaine Dessard
Marketing & Communication Director
rp@biocorp.fr
+ 33 (0)6 88 69 72 85
ULYSSE COMMUNICATION CONTACTS
Bruno ARABIAN
barabian@ulysse-communication.com
+33 (0)6 87 88 46 26
Nicolas DANIELS
ndaniels@ulysse-communication.com
+33 (0)6 63 66 59 22
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Foresight Launches the First Conversational AI Interface to Query Unified Private Market Data23.10.2025 15:07:00 EEST | Press release
Foresight is ushering in the next generation of private market software by letting its customers use natural language to query their unified pre- and post-deal data. Today, the company announced new AI capabilities that will give customers the ability to ask questions within the Foresight platform as well as in ChatGPT, Claude, and Glean through its new model context protocol (MCP) server. Private market dealmakers will be able to prompt Foresight’s AI for lists of prospective companies, and anyone who makes post-deal decisions will be able to ask portfolio questions, model scenarios, and execute workflows in natural language on Foresight’s desktop or mobile interfaces. “The $15 trillion private market has run on data silos and Excel, which has created unnecessary opacity. Foresight unlocks the data and analytics that fund managers and financial institutions need by using AI to unify the systems and sources of private market data and making it actionable through great user interfaces f
CEOs Worldwide Show Rising Confidence and Unprecedented Adaptability Amid Unrelenting Uncertainty23.10.2025 15:00:00 EEST | Press release
Global CEOs are meeting ongoing volatility with renewed confidence and agility, according to The CEO Response, Egon Zehnder’s latest study of 1,235 chief executives. The research reveals that 92% of CEOs believe they must cultivate unprecedented levels of adaptability to lead effectively through current geopolitical and economic disruption. Yet most feel more capable and confident than a year ago, having turned recent crises into lasting lessons in resilience. “CEOs are increasingly adjusting to the rapidly changing world order, characterized by fragmented alliances, strategic resource shortages, new technologies, and the power of individual actors,” said Lars-Hendrik Röller, Founder and Chair of the Berlin Global Dialogue. “They are guided by a key insight: Either they help shape the rules of the new order—or they are completely exposed to its complex developments.” Nearly six in ten CEOs (59%) view agility and adaptability as the most critical factor for business success today, while
The Next Era of Ownership Begins with the All New Ledger Nano™ and Ledger Wallet™23.10.2025 15:00:00 EEST | Press release
Ledger™, the world leader in digital asset security for consumers and enterprises, today unveiled a new era for Ledger, ownership, and identity. At Ledger Op3n in Paris, Ledger launched the new Ledger Nano™ Gen5, recreated and expanded Ledger Live™ as Ledger Wallet™, and introduced Ledger Multisig. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251023549325/en/ As society transitions to digital identities, challenged by AI and a blurring of physical and online worlds, authenticating what's true is critical. Ledger is redefining its products to meet this future head-on, building products to enable Proof of You and Proof of Authority at scale. Ledger’s secure devices, formerly known as hardware wallets, are now Ledger signers. This update reflects their expanded role beyond securing financial transactions, including protecting digital identity in a world accelerated by AI. Ledger signers will continue to operate as millions no
Adtran launches industry-first Galileo OSNMA authentication for Oscilloquartz timing solutions23.10.2025 15:00:00 EEST | Press release
Adtran today announced support for Galileo’s Open Service Navigation Message Authentication (OSNMA) across its Oscilloquartz synchronization platforms, marking a major advance in GNSS security. OSNMA is the first GNSS authentication service designed for civilian use, and Adtran is the first in the timing industry to support it. By verifying that timing data originates from genuine Galileo satellites, OSNMA ensures authenticity and integrity at the point of reception. Available via firmware update for supported multi-band GNSS receivers, the new feature adds an extra layer of protection against spoofing and manipulation, empowering existing deployments to strengthen security without hardware changes or service disruption. “This is a milestone for GNSS security,” said Gil Biran, GM of Oscilloquartz, Adtran. “As the first in the timing industry to support Galileo’s OSNMA service, we’re setting a new standard for authenticated satellite synchronization. From 5G and smart power grids to fin
KILL TOURISE and Globant Unveil Game-Changing Report on Agentic Tourism that Sets New Standards for AI-Driven Destination Innovation23.10.2025 11:30:00 EEST | Press release
TOURISE requests that their press release NewsItemID: 20251022347041 “TOURISE and Globant Unveil Game-Changing Report on Agentic Tourism that Sets New Standards for AI-Driven Destination Innovation” be killed. The release was issued in error by TOURISE. A replacement release will be issued on October 23.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom